Literature DB >> 12781797

Prenatal diagnosis for chromosome abnormalities: past, present and future.

Caroline Mackie Ogilvie1.   

Abstract

Prenatal diagnosis for chromosome abnormalities has been available for over 30 years. The most common referral indication is a raised risk of Down's syndrome, and diagnosis has, until recently, been carried out by culture of cells from invasive prenatal sampling, followed by full karyotype analysis, with a waiting time of around 2 weeks for results. More recent developments in fluorescence in situ hybridisation (FISH) and quantitative fluorescence-PCR techniques have led to rapid 1-2 d reporting for Down's syndrome, opening the way to the possibility of targeted testing based on referral indication, thus reducing the incidence of difficult counselling issues and potentially unnecessary pregnancy terminations following the unexpected discovery of anomalies such as balanced chromosome rearrangements. The future of prenatal diagnosis must lie in the non-invasive diagnosis of Down's syndrome using fetal cells from maternal circulation.

Entities:  

Mesh:

Year:  2003        PMID: 12781797     DOI: 10.1016/s0369-8114(03)00017-8

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  7 in total

1.  Rapid aneuploidy detection or karyotyping? Ethical reflection.

Authors:  Antina de Jong; Wybo J Dondorp; Daniëlle R M Timmermans; Jan M M van Lith; Guido M W R de Wert
Journal:  Eur J Hum Genet       Date:  2011-06-01       Impact factor: 4.246

2.  Rare chromosome abnormalities, prevalence and prenatal diagnosis rates from population-based congenital anomaly registers in Europe.

Authors:  Diana Wellesley; Helen Dolk; Patricia A Boyd; Ruth Greenlees; Martin Haeusler; Vera Nelen; Ester Garne; Babak Khoshnood; Berenice Doray; Anke Rissmann; Carmel Mullaney; Elisa Calzolari; Marian Bakker; Joaquin Salvador; Marie-Claude Addor; Elizabeth Draper; Judith Rankin; David Tucker
Journal:  Eur J Hum Genet       Date:  2012-01-11       Impact factor: 4.246

3.  Is routine karyotyping required in prenatal samples with a molecular or metabolic referral?

Authors:  Angelique Ja Kooper; Jacqueline Jpm Pieters; Brigitte Hw Faas; Lies H Hoefsloot; Ineke van der Burgt; Hans A Zondervan; Arie Pt Smits
Journal:  Mol Cytogenet       Date:  2012-01-27       Impact factor: 2.009

4.  High-resolution whole-mount in situ hybridization using Quantum Dot nanocrystals.

Authors:  Andriani Ioannou; Iro Eleftheriou; Andrea Lubatti; Anna Charalambous; Paris A Skourides
Journal:  J Biomed Biotechnol       Date:  2012-01-12

5.  Prenatal Diagnosis of Chromosome Abnormalities: A 13-Year Institution Experience.

Authors:  Carmen Comas; Mónica Echevarria; María Ángeles Rodríguez; Ignacio Rodríguez; Bernat Serra; Vincenzo Cirigliano
Journal:  Diagnostics (Basel)       Date:  2012-11-19

6.  Rapid detection of fetal aneuploidies by quantitative fluorescent-polymerase chain reaction for prenatal diagnosis in the Turkish population.

Authors:  Ai Guzel; Mb Yilmaz; O Demirhan; A Pazarbasi; S Kocaturk-Sel; Ma Erkoc; N Inandiklioglu; Ft Ozgunen; C Sariturk
Journal:  Balkan J Med Genet       Date:  2012-06       Impact factor: 0.519

7.  Fetal cardiac examination can affect patients' preference on invasive tests: A new data on maternal anxiety indicated karyotyping.

Authors:  Emre Ekmekci; Servet Gencdal; Emine Demirel; Sefa Kelekci
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.